Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Receivables (2020 - 2025)

RxSight (RXST) has disclosed Change in Receivables for 6 consecutive years, with -$788000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 116.83% year-over-year to -$788000.0, compared with a TTM value of -$6.7 million through Dec 2025, down 167.89%, and an annual FY2025 reading of -$6.7 million, down 167.89% over the prior year.
  • Change in Receivables was -$788000.0 for Q4 2025 at RxSight, up from -$3.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.0 million in Q4 2023 and bottomed at -$3.9 million in Q3 2025.
  • Average Change in Receivables over 5 years is $1.0 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Change in Receivables surged 566.45% in 2024, then tumbled 1120.94% in 2025.
  • Year by year, Change in Receivables stood at $504000.0 in 2021, then skyrocketed by 283.93% to $1.9 million in 2022, then soared by 160.31% to $5.0 million in 2023, then decreased by 7.05% to $4.7 million in 2024, then crashed by 116.83% to -$788000.0 in 2025.
  • Business Quant data shows Change in Receivables for RXST at -$788000.0 in Q4 2025, -$3.9 million in Q3 2025, and -$2.9 million in Q2 2025.